Dec 19 (Reuters) - Phio Pharmaceuticals Corp PHIO.O:
PHIO PHARMACEUTICALS: POSITIVE SAFETY MONITORING COMMITTEE RECOMMENDATION TO CONTINUE TO THIRD DOSE COHORT IN ITS CLINICAL STUDY OF PH-762
INTRATUMORAL INJECTIONS HAVE BEEN WELL TOLERATED
NO DOSE-LIMITING TOXICITIES, OR SERIOUS ADVERSE EVENTS IN PARTICIPANTS RECEIVING INTRATUMORAL PH-762
Source text: [ID:n0001683168-24-008833]
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。